The New England Journal of Medicine Publishes Positive Phase 3 RESPONSE Data of CymaBay’s Seladelpar in Primary Biliary Cholangitis
– Seladelpar demonstrated normalization of liver biomarkers and significant reductions across three measures of patient-reported itch vs. placebo –
NEWARK, Calif., Feb. 21, 2024 /PRNewswire/ — CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that The New England Journal of Medicine (NEJM) has published detailed results from the RESPONSE Phase 3 trial evaluating seladelpar, an investigational agent, and the only potent, selective peroxisome proliferator-activated receptor delta (PPARδ) agonist or delpar, being studied in adults with primary biliary cholangitis (PBC). Results showed rapid and sustained improvements in reducing cholestasis and liver injury, together with significant reductions in pruritus (itching) across the numerical rating scale (NRS), 5-D Itch Scale, and the PBC-40 questionnaire. Publication of these detailed findings from RESPONSE follows topline data presented as a late breaker at The Liver Meeting® 2023 of the American Association for the Study of Liver Diseases (AASLD) in November 2023.